What Happened To Juno Therapeutics
Juno Therapeutics
Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an init…
NASDAQ
The Nasdaq Stock Market is an American stock exchange. It is the second-largest stock exchange in the world by market capitalization, behind only the New York Stock Exchange located in the same city. The exchange platform is owned by Nasdaq, Inc., which also owns the Nasdaq Nordic and Na…
Full Answer
What is Juno Therapeutics'(Juno) stock price?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO." What is Juno Therapeutics' stock price today? One share of JUNO stock can currently be purchased for approximately $86.96. What is Juno Therapeutics' official website? The official website for Juno Therapeutics is www.junotherapeutics.com.
How much did Juno raise from its IPO?
(JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.
What does Juno Therapeutics do?
The Company focuses on developing immunotherapies for cancer and other research services. Juno Therapeutics serves the healthcare sector in the United States. NO. OF EMPLOYEES
What happened Juno stock?
On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene....Juno Therapeutics.TypeSubsidiaryParentBristol-Myers SquibbWebsitewww.bms.com5 more rows
Is Juno publicly traded?
Juno Therapeutics, Inc. is offering shares of common stock. This is our initial public offering and no public market currently exists for our shares.
Who bought out Juno?
CelgeneA few months later, in January 2018, Celgene acquired Juno in a $9 billion deal. The New Jersey-based biotech company continues to operate Juno's Seattle R&D space and its manufacturing facility in nearby Bothell, Wash. Giovanni Caforio, Bristol-Myers Squibb CEO.
What is the stock symbol for Celgene?
CELGCelgene Corp (CELG)
Is Fred Hutch publicly traded?
Fred Hutch remains a significant investor in the company, holding 4.6 percent of Juno's shares. At $23 a share, the Hutch's shares would be worth $90 million at the IPO. Juno's largest shareholder is CL Alaska LP and JT Line Partners LP, which holds about 32 percent of the company's stock.
Who founded Juno?
Juno co-founders Rick Klausner, former global health director of the Bill & Melinda Gates Foundation, and Fred Hutch investigator Stan Riddell are co-founders of Lyell Immunopharma, which has operations in the Seattle area and went public in a $425 million IPO this summer.
Where is Juno Therapeutics located?
SeattleThe biopharmaceutical company is engaged in developing innovative cellular immunotherapy drugs for the treatment of cancer. Covering 90,000ft², the new headquarters is located in a 375,000ft² lab and office building at 400 Dexter Avenue North, South Lake Union, Seattle.
What company owns Celgene?
Bristol Myers SquibbCelgene / Parent organizationThe Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2021, it had a total revenue of $46.4 billion. Wikipedia
Can I still buy Celgene stock?
It's not too late to buy Celgene stock at all -- as long as you hold on to the Bristol-Myers Squibb stock you get when the acquisition closes.
What happened Celgene stock?
Celgene common stock ceased trading as of the close of trading today. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol “BMYRT.”
Did BMS acquire Celgene?
By erasing one of the industry's most active partners, the $74 billion deal promises to shake up biotech for years to come.
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS f...
Who are Juno Therapeutics' key executives?
Juno Therapeutics' management team includes the following people: Howard H. Pien , Independent Chairman of the Board (Age 59) Hans Edgar Bishop...
What other stocks do shareholders of Juno Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (CELG) , (KITE)...
When did Juno Therapeutics IPO?
(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15...
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics' official website?
The official website for Juno Therapeutics is www.junotherapeutics.com .
How can I contact Juno Therapeutics?
Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States . The biopharmaceutical company can be reac...
Who is the CEO of Juno?
Image source: Getty Images. Here's what Juno's CEO Hans Bishop had to say about the deal: "The people at Juno channel their passion for science and patients toward a common goal of finding cures by creating cell therapies that help people live longer, better lives.
Who is the CEO of Celgene?
And here is Celgene's CEO Mark Alles' commentary on the acquisition: "The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers.
